PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Local nasal immunotherapy (LNIT) significantly reduced clinical symptoms and drug intake compared to placebo [PMID:12947995].
Sublingual immunotherapy with monomeric allergoids showed clear improvement in clinical and drug consumption scores [PMID:16752693].
Sublingual immunotherapy with specific allergens resulted in marked improvement of sneezing, itching of the eyes, and rhinitis in 12 out of 14 patients [PMID:8940498].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 41079755 (2024) — The genome sequence of pellitory-of-the-wall, Parietaria judaica L. (Urticaceae). · Wellcome open research
- 2.PMID: 12660421 (2003) — The allergens of Parietaria. · International archives of allergy and immunology
- 3.PMID: 16752693 (2006) — Monoid sublingual immunotherapy. · European annals of allergy and clinical immunology
- 4.PMID: 30544607 (2018) — Parietaria Allergy: An Intriguing Challenge for the Allergist. · Medicina (Kaunas, Lithuania)
- 5.PMID: 25284812 (2015) — Multiple IgE recognition on the major allergen of the Parietaria pollen Par j 2. · Molecular immunology